Casals-Stenzel J, Franke J, Friedrich T, Lichey J
Boehringer Ingelheim KG, Ingelheim, F.R.G.
Br J Pharmacol. 1987 Aug;91(4):799-802. doi: 10.1111/j.1476-5381.1987.tb11278.x.
1 The effect of the platelet-activating factor (Paf) antagonist, WEB 2086, on Paf-induced increase of pulmonary artery perfusion pressure (Pp), bronchial inflation pressure (Pi) and wet-to-dry lung weight ratios (W/D) was investigated in the rat isolated lung. 2 Lungs were perfused with Krebs-Ringer solution (KRS) as controls or with KRS containing WEB 2086 (0.1, 1.0, 10.0 or 100 micrograms ml-1) and then injected with a bolus of 20 micrograms Paf. 3 A dose-related inhibition of the Paf-induced increase of Pp, Pi and W/D was observed, being almost maximal for the 10.0 micrograms ml-1 and complete for the 100 micrograms ml-1 doses of WEB 2086 when compared to controls. 4 It is concluded that WEB 2086 is a highly effective and specific Paf antagonist in the pulmonary vasculature and bronchial tract.
1 在大鼠离体肺中研究了血小板活化因子(Paf)拮抗剂WEB 2086对Paf诱导的肺动脉灌注压(Pp)、支气管充气压力(Pi)和肺湿重与干重比(W/D)升高的影响。2 用 Krebs-Ringer 溶液(KRS)灌注肺作为对照,或用含 WEB 2086(0.1、1.0、10.0 或 100 微克/毫升)的 KRS 灌注,然后注射 20 微克 Paf 推注剂量。3 观察到对 Paf 诱导的 Pp、Pi 和 W/D 升高有剂量相关的抑制作用,与对照相比,对于 10.0 微克/毫升的 WEB 2086 剂量,抑制作用几乎达到最大,对于 100 微克/毫升的剂量,抑制作用完全。4 结论是,WEB 2086 在肺血管系统和支气管中是一种高效且特异性的 Paf 拮抗剂。